Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Melanotan I / Afamelanotide

The commercial label Melanotan I is commonly associated with afamelanotide, a synthetic alpha-MSH analogue, but catalogue-material equivalence is not verified. The labeled evidence comes from three randomized implant trials in 244 adults with EPP, not general tanning or an injectable vial.

Aliases reviewed
MT-1, Afamelanotide, Scenesse
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
Not rated
Animal/cell
Not rated
Approved medicine
Approved product existsOne U.S.-approved afamelanotide implant; a 5 mg vial is not that product.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. MC1 receptor agonism increases eumelanin and has been studied in photoprotection and pigmentation biology.

Identity

The commercial label Melanotan I is commonly associated with afamelanotide, a synthetic alpha-MSH analogue, but catalogue-material equivalence is not verified.

Biological mechanism or research interest

MC1 receptor agonism increases eumelanin and has been studied in photoprotection and pigmentation biology.

Verified approved human uses

FDA-approved Scenesse is a 16 mg bioresorbable afamelanotide implant to increase pain-free light exposure in adults with erythropoietic protoporphyria. A 5 mg vial is not that product.

Investigational human evidence

The labeled evidence comes from three randomized implant trials in 244 adults with EPP, not general tanning or an injectable vial.

Consumer tanning, photoprotection outside EPP, and cosmetic claims do not follow from the narrow implant approval.

Human versus animal or cell evidence

MC1 receptor and pigment findings explain mechanism but do not transfer formulation-specific safety or benefit.

Limitations and known risks

The label describes hypersensitivity, skin pigmentation changes, and the need to monitor pigmented lesions; catalogue identity and sterility are unknown.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.